• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 3:27:37 PM ET
    $CHMA
    Major Pharmaceuticals
    Health Care
    Get the next $CHMA alert in real time by email
    SC 13G/A 1 chma13ga2.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    Chiasma, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    16706W102

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 16706W102

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person -0-

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     

     2 
    CUSIP No. 16706W102

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person -0-

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     3 
    CUSIP No. 16706W102

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person -0-

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 16706W102

     

     

    Item1.
    (a)Name of Issuer

    Chiasma, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    140 Kendrick Street, Building C East, Needham, Massachusetts 02494
    ________________________________________________________________________
    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, $0.01 par value (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 1670W102.
     5 
    CUSIP No. 16706W102

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The funds managed by EcoR1, including Qualified Fund, hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2021

     

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

     

     6 
    CUSIP No. 16706W102

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 12, 2021

     

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

     

    Get the next $CHMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHMA
    Financials

    Live finance-specific insights

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q1 2022 Results

      Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c

      5/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $CHMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chiasma downgraded by Jefferies

      Jefferies downgraded Chiasma from Buy to Hold

      5/6/21 8:05:49 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • HC Wainwright resumed coverage on Chiasma with a new price target

      HC Wainwright resumed coverage of Chiasma with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      3/2/21 7:26:29 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Chiasma, Inc.

      EFFECT - CHIASMA, INC (0001339469) (Filer)

      8/12/21 12:15:07 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Chiasma, Inc.

      15-12B - CHIASMA, INC (0001339469) (Filer)

      8/11/21 4:31:58 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Chiasma, Inc.

      S-8 POS - CHIASMA, INC (0001339469) (Filer)

      8/6/21 3:17:41 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CHMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)

      SC 13G/A - CHIASMA, INC (0001339469) (Subject)

      8/9/21 4:06:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/24/21 4:29:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/7/21 4:29:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/9/21 5:01:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: LUDLAM WILLIAM returned 11,799 units of Common Stock to the company, closing all direct ownership in the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:05:08 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Mamluk Roni

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:00:07 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Leadership Updates

    Live Leadership Updates

    See more
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

      Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the fourth quar

      3/4/21 4:01:00 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care